[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Intercommunal Creteil\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":636},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,40,73,102,122,142,168,188,207,233,250,277,300,325,359,385,417,437,461,489,518,542,564,584,612],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100053566","envieancillaire-efficacy-of-nirsevimab-in-children-hospitalised-with-rsv-bronchiolitis---a-subsidiary-study-on-the-immune-signature-and-microbial-environment-100053566",false,"NCT07698769","ENVIEANCILLAIRE: Efficacy of Nirsevimab in Children Hospitalised With RSV Bronchiolitis - A Subsidiary Study on the Immune Signature and Microbial Environment","ENVIEANCILLAIR","Inclusion Criteria:\n\n* Written consent to take part in the study\n* Registered with a social security scheme\n\nCases:\n\n* Children aged 6 months or under included in the ENVIE study. Treated for bronchiolitis caused by RSV\n* Admitted to hospital following a visit to the paediatric A\\&E department\n\nControl group:\n\nChildren aged 6 months or under included in the ENVIE study. Admitted to a standard ward or a Short-Stay Unit, or having attended the paediatric A\\&E department\n\nFor one of the following reasons:\n\n* Febrile urinary tract infection, without acute ENT or respiratory symptoms\n* Acute gastroenteritis, without acute ENT or respiratory symptoms\n* Infant colic without fever, without ENT or acute respiratory condition\n* Weight stagnation or feeding difficulties without fever, without acute ENT or respiratory symptoms\n* Neonatal jaundice without fever, without acute ENT or respiratory symptoms\n* Unexplained crying without fever, without acute ENT or respiratory symptoms\n* Head injury, without acute ENT or respiratory symptoms\n* Admitted for acute surgical conditions, without fever, without acute ENT or respiratory symptoms\n* Nappy rash, without fever, without acute ENT or respiratory symptoms\n* Fracture, without fever, without acute ENT or respiratory symptoms.\n\nExclusion Criteria:\n\n* Refusal to participate by the legal representative\n* Administration of palivizumab\n* Maternal vaccination against RSV.","ALL","0 Months","6 Months",{"count":21,"type":22},110,"ESTIMATED","OBSERVATIONAL","Among children aged ≤ 6 months included in the ENVIE study, the ENVIE\\_ancillaire study will be offered to cases of RSV infection or to controls. The study involves a nasopharyngeal swab using a FLOQ-SWAB™ swab and a fingertip sample (dextro type). These samples will be collected specifically for the purpose of studying immunity.\n\nA blood sample may also be requested for children weighing ≥5 kg who are included in the ENVIE\\_ancillaire study. The purpose of this sample collection will be to conduct an advanced immunological study",[26],"Mucosal Cytokine Profile of Patients (Type I and III Interferons, Pro-inflammatory Cytokines)","RECRUITING","2026-07-07",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":31},"2024-12-05",{"date":35,"type":22},"2026-12-05",{"name":37,"class":38},"Centre Hospitalier Intercommunal Creteil","OTHER",3,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":17,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100632389","diaphragmatic-swing-according-to-cpap-flow-output-in-neonates-disconeo-100632389","NCT07513051","DIaphragmatic Swing According to Cpap Flow Output in NEOnates (DISCONEO)","Diaphragmatic Activity During Constant or Variable Flow CPAP in Neonates: a Non-inferiority, Randomized, Alternating Treatments Trial","Above mentioned age limits (72 hours to 10 weeks) apply to postnatal age. Inclusion criteria apply to gestational age at birth and postmenstrual age (in weeks).\n\nInclusion Criteria:\n\n* Neonates born at ≤ 32 weeks GA (gestational age)\n* Hospitalized in our tertiary hospital NICU (Neonatal intensive care unit)\n* Receiving CPAP since \\> 24 hours at inclusion\n* Equipped with EAdi catheters.\n* Aged more than 72 hours\n* With parental consent\n* Affiliated to or benefiting from a social security system\n\nNon inclusion Criteria:\n\n* More than 1 episode of apnea \u002F hour and\u002For hypercapnic acidosis (defined as pH \\\u003C 7.20 and\u002For pCO2 \\> 65)\n* FiO2 \\> 60%\n* Neonatal ARDS (acute respiratory distress syndrome) according to the Montreux definition\n* Pneumothorax\u002F pneumomediastinum\n* Nasal lesions contraindicating nasal noninvasive ventilation\n* Major congenital malformation\u002FChromosomopathies\n* Congenital neuromuscular diseases\n* Hemodynamic instability","72 Hours","10 Weeks",{"count":50,"type":22},20,"INTERVENTIONAL",[53],"NA","The hypothesis behind the study is that the performance of constant flow CPAP (Continuous Positive Airway Pressure) devices (CF-CPAP) is not inferior to that of variable flow CPAP devices (VF-CPAP) in terms of respiratory efforts assessed by swing EAdi (Electrical activity of diaphragm) in a population of premature neonates born ≤ 32 weeks of gestational age.",[56],"Neonatal Respiratory Distress",[58,59,60,61,62,63],"Continuous Positive Airway Pressure (CPAP)","Variable flow Continuous Positive Airway Pressure (VF-CPAP)","Constant flow Continuous Positive Airway Pressure (CF-CPAP)","Respiratory Effort","Infant comfort","Diaphragmatic electrical activity (EADi)","2026-06-22",{"date":66,"type":31},"2026-06-23",{"date":68,"type":31},"2026-06-10",{"date":70,"type":22},"2027-12-12",{"name":37,"class":38},1,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100643924","study-of-occupational-risk-factors-for-biliary-and-pancreatic-cancers-100643924","NCT07668024","Study of Occupational Risk Factors for Biliary and Pancreatic Cancers","PANTOXBIL","Inclusion Criteria:\n\n* Cases :\n\n  * Patients included in the TEDOPAM or IMMUNOBIL trials\n  * Diagnosis of biliary tract or pancreatic cancer\n  * Completed and exploitable curriculum laboris\n* Controls :\n\n  * Subjects from the CHOPPI cohort\n  * Age ≥ 18 years\n  * No biliary tract or pancreatic cancer\n  * No known familial predisposition to biliary tract or pancreatic cancers\n  * No opposition to data reuse\n\nExclusion Criteria:\n\n* Incomplete or non-exploitable occupational history\n* Refusal of data reuse","18 Years",{"count":82,"type":22},210,"PANTOXBIL is a research project developed in the context of the increasing incidence of biliary tract and pancreatic cancers in France. Despite recent therapeutic advances, the prognosis of these cancers remains poor. Known risk factors do not fully explain the increase in incidence observed over recent decades. This suggests the possible role of emerging occupational and environmental risk factors, as reported in several epidemiological studies.\n\nThe PANTOXBIL study is based on the analysis of detailed curriculum laboris data (employment periods, occupations, tasks performed, and occupational exposures) collected during two multicenter phase II clinical trials, TEDOPAM and IMMUNOBIL, conducted between 2018 and 2021 in patients with pancreatic and biliary tract cancers.\n\nAn occupational exposure assessment was performed to calculate semi-quantitative cumulative exposure indices for each exposure or group of exposures for every participant. These indices will be compared with those of healthy controls from the CHOPPI cohort, initially designed to study occupational risk factors in COPD.\n\nPANTOXBIL is a matched case-control study based on sex, age, and smoking status. The aim is to compare cumulative occupational exposure indices between cases and controls in order to generate new hypotheses regarding occupational risk factors for biliary tract and pancreatic cancers.",[85,86],"Biliary Tract Cancer","Pancreatic Cancer",[88,89,90,91,92],"Biliopancreatic cancers","Occupational exposure","Cumulative exposure index","Curriculum laboris","Case-control study","NOT_YET_RECRUITING","2026-06-19",{"date":96,"type":31},"2026-06-25",{"date":98,"type":22},"2026-08",{"date":100,"type":22},"2026-09",{"name":37,"class":38},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":72},"100510069","short--and-medium-term-evaluation-of-mastoid-filling-using-bioactive-glass-100510069","NCT05921643","Short- and Medium-term Evaluation of Mastoid Filling Using Bioactive Glass\"","GLASS-BONA","Inclusion Criteria:\n\n* Patients at least 18 years old\n* Patients with proven cholesteatoma\n* Patient requiring and agreeing to surgery with filling of the mastoid or tympanic epi (closed technique with filling)\n* Patient having a surgery with filling in first intention\n\nExclusion Criteria:\n\n* Background:\n* Known outer, middle or inner ear malformation\n* Congenital cholesteatoma\n* Previously operated cholesteatoma\n* Cholesteatoma requiring an open technique or presenting with chronic non-cholesteatomatous otitis\n* Contraindications to the use of GlassBONE™ or Bonalive™\n* Pregnant, parturient or nursing mothers\n* Persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care, adults subject to a measure of legal protection or unable to express themselves\n* Patient participating in interventional research excluding routine care research (old regulations) and category 2 research that does not interfere with the analysis of the primary endpoint\n* Patient objecting to the use of their data",{"count":110,"type":22},70,"Adult patients referred to the ENT surgery department of the Hospices Civils de Lyon with cholesteatoma that had never been operated on.\n\nAll patients will benefit from surgical management for cholesteatoma initially in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence.",[113],"Cholesteatoma","2026-06-15",{"date":116,"type":31},"2026-06-16",{"date":118,"type":31},"2023-09-29",{"date":120,"type":22},"2030-04",{"name":37,"class":38},{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":72},"100472846","study-of-microbiological-diversity-in-exhaled-air-in-copd-and-free-of-copd-100472846","NCT05437198","Study of Microbiological Diversity in Exhaled Air in COPD and Free of COPD","Study of Microbiological Diversity in Exhaled Air in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Subjects Free of COPD","EXHALBIO","Inclusion Criteria:\n\nFor COPD:\n\n* Patients with chronic obstructive pulmonary disease\n* Age: over 18\n\nFor non-COPD\n\n* Absence of chronic obstructive pulmonary disease\n* Age: between 18 and 30 years old and between 45 and 70 years old\n\nExclusion Criteria:\n\n* Taking certain medications in the month preceding the sample (antibiotics, systemic corticosteroids, immunosuppressants)\n* Person under guardianship or curatorship\n* Pregnant or breastfeeding women\n* Person unable to express his\u002Fher opposition, person deprived of liberty\n* Existence of a chronic infectious pulmonary pathology such as (dilation of the bronchi, cystic fibrosis)","70 Years",{"count":132,"type":22},240,"COPD and non-COPD patients will be included in the study after collection of their non-objection. The exhalation will be collected to study the microbiological diversity of human exhalations.\n\na second collection for the year +1 will be made, at the same time (between October and March).",[135],"Chronic Obstructive Pulmonary Disease",{"date":116,"type":31},{"date":138,"type":31},"2024-03-26",{"date":140,"type":22},"2029-03",{"name":37,"class":38},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":17,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":51,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":72},"100642221","octa-evaluation-of-retinal-vascularization-in-preterm-infants-with-or-without-bronchopulmonary-dysplasia-100642221","NCT07586683","OCTA Evaluation of Retinal Vascularization in Preterm Infants With or Without Bronchopulmonary Dysplasia","OCTA_BRO","Inclusion Criteria:\n\n* Preterm group:\n\nAny child aged 5 to 15 years born at or before 28 weeks' gestation (with or without bronchopulmonary dysplasia), followed or not at CHIC.\n\n-Control group: Any child aged 5 to 15 years born at or after 38 weeks' gestation, attending ophthalmology consultations at CHIC.\n\n* Agreement to participate in the study protocol\n* Child living near CHI Créteil\n* Enrolled in a social security scheme\n\nExclusion Criteria:\n\n* Neurobehavioral disorders or psychomotor delay preventing the examination from being performed\n* Presence of ROP (retinopathy of prematurity) involving zone I or having received intravitreal injections (IVT) of anti-VEGF (as this may directly alter OCT-A parameters)\n* Pre-existing retinal disease: macular scar of any cause, retinal vascular abnormalities such as sickle cell disease or diabetes\n* Pre-existing optic nerve diseases: glaucoma, coloboma, tumors\n* Chronic respiratory diseases other than BPD (bronchopulmonary dysplasia) (i.e., not associated with prematurity): cystic fibrosis, bronchiectasis, etc.\n* General condition unrelated to prematurity that may have a retinal impact: for example respiratory diseases other than BPD\n* Participation in an interventional ophthalmology study\n* History of febrile seizures in infancy or epilepsy contraindicating the use of eye drops","5 Years","15 Years",{"count":152,"type":22},56,[53],"Retinal vascularization in humans develops between the 16th and 36th weeks of amenorrhea, in a centrifugal pattern starting from the optic disc. In the case of premature birth, the immature peripheral retina is at risk of ischemia due to incomplete vascular development.\n\nPrematurity is often associated with respiratory fragility. It frequently requires ventilatory support in the form of oxygen therapy, either invasive (orotracheal intubation) or non-invasive, which induces reflex arteriolar vasoconstriction, thereby worsening the existing ischemia. This raises the question of whether subclinical retinal vascular changes, detectable by OCT angiography, may explain the increased risk of amblyopia and the need for optical correction observed in these patients.\n\nOCT angiography is rapidly expanding in the field of retinal vascular diseases: it is a simple, fast, reliable, and non-invasive examination, requiring no injection, that enables high-resolution visualization of retinal vascularization, with separate analysis of the retinal plexuses and the choriocapillaris.",[156],"Bronchopulmonary Dysplasia",[158,159,160],"OCT_A","children born prematurely","Bronchopulmonary dysplasia","2026-06-11",{"date":114,"type":31},{"date":164,"type":22},"2026-06",{"date":166,"type":22},"2028-05",{"name":37,"class":38},{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":4},"100628000","towards-an-understanding-of-barriers-and-delays-in-the-diagnosis-of-anal-cancer-100628000","NCT07455942","Towards an Understanding of Barriers and Delays in the Diagnosis of Anal Cancer","FRACAS","Inclusion Criteria:\n\n1. Male or female ≥ 18 years\n2. Histologically proven invasive or microinvasive squamous cell carcinoma of the anus\n3. Having read and understood the information letter provided, either:\n\n   i. After disclosure of the diagnosis, or ii. At the latest 6 months after initiation of treatment (surgical excision, radiotherapy, or chemoradiotherapy)\n4. Affiliated with a social security system\n\nExclusion Criteria:\n\n1. Refusal to participate in the protocol\n2. Other histological types: lymphoma, adenocarcinoma, neuroendocrine tumor, etc.\n3. Time since treatment initiation greater than 6 months\n4. Protected persons (pregnant women, breastfeeding women, individuals under guardianship or curators, minors, persons deprived of liberty, or persons unable to express informed consent).",{"count":176,"type":22},300,"This study examines care pathways in 300 patients with anal squamous cell carcinoma to identify barriers and delays in diagnosis, assess the impact of screening and access to care, and improve awareness, screening practices, and early diagnosis.",[179,180],"Squamous Cell Carcinoma of the Anal Canal","HPV-induced Cancer",{"date":182,"type":31},"2026-06-12",{"date":184,"type":22},"2026-06-30",{"date":186,"type":22},"2028-12-31",{"name":37,"class":38},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":72},"100423828","bronchi-dilation-in-polynesian-patients-monocentric-retrospective-study-100423828","NCT04798950","Bronchi Dilation in Polynesian Patients: Monocentric Retrospective Study","Inclusion Criteria:\n\n* Polynesian patient\n* Patient with bronchial dilation followed by Centre hospitalier de Polynesie Francaise or patient with bonchial dilation no longer consulting in the hospital over the study period Jan 1, 2010 to Dec 31, 2020\n\nExclusion Criteria:\n\n* Expressed refusal to participate in the study for patients undergoing follow-up",{"count":195,"type":22},500,"The study hypothesis is that dilations of idiopathic bronchi are particularly common in French Polynesia, and that there are arguments in favour of an underlying genetic factor.\n\nThe study will retrieve retrospective data in the history of bronchial dilation, patients' personal and family history, microbiological and scannographic data, and the latest cardio respiratory checkup.",[198],"Polynesian Bronchiectasis",[200],"bronchi dilatation",{"date":114,"type":31},{"date":203,"type":31},"2025-06-01",{"date":205,"type":22},"2027-06-01",{"name":37,"class":38},{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":215,"minAge":80,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":51,"phases":217,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":50},"100389856","phase-3-chronic-hypertension-and-acetyl-salicylic-acid-in-pregnancy-100389856","NCT04356326","Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy","Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a Multicenter Prospective Randomized Double-blind Placebo-controlled Trial.","CHASAP","Inclusion Criteria:\n\n* Pregnant patient between 10 and 19 weeks of gestation + 6 days\n* Chronic hypertension, whether treated or not, know before pregnancy or diagnosed before randomization\n* Singleton pregnancy\n* Signed the written informed consent\n* Affiliation to social security\n\nExclusion Criteria:\n\n* ---Medical history requiring anticoagulation (antiphospholipid syndrome, deep vein thromboembolic disease, pulmonary embolism, atherothrombosis, patient with mechanical heart valves),\n* Patient receiving aspirin for another indication outside pregnancy,\n* Patient with significant proteinuria (\\> 300mg\u002F24 hours or a proteinuria\u002Fcreatininuria ratio ≥ 30mg\u002Fmmol),\n* Active bleeding,\n* History of severe PE with delivery \\\u003C 34 weeks of gestation,\n* Hypersensitivity to salicylates such as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs),\n* Platelet count lower than 100,000 cells\u002Fmicroliter (dosage less than 6 months old),\n* Hemostasis disorders, including hemophilia (with thrombocytopenia)\n* Any constitutional or acquired hemorrhagic disease, (including digestive hemorrhages, history of hemorrhagic stroke and thrombocytopenia\n* Human immunodeficiency virus, or hepatitis B virus, or hepatitis C virus positive serum,\n* Patient included in another interventional study which could interfere with the results of the study,\n* Age \\\u003C18 years old,\n* Women under the protection of justice,\n* Patients with psychiatric follow-up, poor understanding of French or cognitive problems,\n* Duodenal ulcer,\n* Severe renal impairment,\n* Severe hepatic insufficiency,\n* Severe cardiac impairment,\n* Gout,\n* Patients with known glucose-6-phosphate dehydrogenase deficiency,","FEMALE",{"count":195,"type":22},[218],"PHASE3","A randomized clinical trial to assess the efficiency of acetylsalicylic acid (aspirin) 150 mg\u002Fday started before 20 weeks of gestation in the prevention on maternal and fœtal complications in pregnant women with chronic hypertension.",[221,222,223,224,225,226],"Chronic Hypertension Complicating Pregnancy","Pre-Eclampsia","Intrauterine Growth Restriction","Aspirin","Perinatal Death","Placental Abruption",{"date":182,"type":31},{"date":229,"type":31},"2021-02-15",{"date":231,"type":22},"2030-02",{"name":37,"class":38},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":215,"minAge":80,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":72},"100333814","study-of-the-physiology-of-pre-eclampsia-and-vascular-iugr-with-constitution-of-a-biological-collection-100333814","NCT03626233","Study of the Physiology of Pre-eclampsia and Vascular IUGR With Constitution of a Biological Collection","Study of the Physiology of Pre-eclampsia and Vascular Intrauterine Growth Restriction With Constitution of a Biological Collection","CPVP","Inclusion Criteria:\n\n* pregnant women\n* With or without vascular pathology\n\nExclusion Criteria:\n\n* refusal to participate\n* multiple pregnancy\n* major fetal malformation diagnosed during pregnancy follow-up",{"count":195,"type":22},"Preeclampsia and intrauterine growth retardation (IUGR) are serious and frequent pathologies, specific to pregnancy. They represent 70 000 new cases a year, or 9% of pregnancies and cause 50,000 premature births per year in France. The consequences in terms of morbidity and perinatal morbidity and the medical and economic costs make it an issue public health. Pre-eclampsia associates maternal hypertension with dysfunction kidney. There is no cure for pre-eclampsia or IUGR vascular during pregnancy. These pathologies invariably evolve towards a maternal and \u002F or fetal aggravation sometimes very fast. Primary prevention and secondary education and screening for these pathologies are still insufficient. A better understanding of the pathophysiology of these placental vascular pathologies is necessary for the development of supported medical, obstetric and pediatric that will improve the state of health maternal and neonatal",[222],{"date":182,"type":31},{"date":246,"type":31},"2018-08-06",{"date":248,"type":22},"2028-08",{"name":37,"class":38},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":260,"conditions":261,"keywords":265,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":39},"100635948","post-emergency-optimization-of-antibiotic-therapy-for-urinary-tract-infection-uti-100635948","NCT07559318","Post-Emergency Optimization of Antibiotic Therapy for Urinary Tract Infection (UTI)","Post-Emergency Optimization of UTI Antibiotic Therapy: \"Fluoroquinolones and Third-Generation Cephalosporins Under the Spotlight\"","REVIU48","Inclusion Criteria:\n\n* Age 18 years or over\n* Patients presenting at emergency department, with symptoms suggestive of a urinary tract infection suitable for outpatient management (uncomplicated cystitis or cystitis at risk of complications, uncomplicated pyelonephritis or pyelonephritis at risk of complications, male urinary tract infection with or without fever) who have had a urine culture taken\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Vulnerable person (person under guardianship or trusteeship, minor, person deprived of liberty, person unable to express their refusal)\n* Pregnant women\n* Severe urinary tract infection (sepsis, septic shock or requiring drainage, except for low urinary catheterisation)\n* Hospitalisation for a urinary tract infection or decompensation of another comorbidity\n* Suspected urinary tract infection without a urine culture having been performed",{"count":259,"type":22},330,"Prospective, multicenter, non-interventional study conducted over 6 months, including patients presenting to the emergency department with suspected urinary tract infection managed as outpatients and discharged with or without empiric antibiotic therapy.\n\nDischarge antibiotic prescriptions are reviewed, with subsequent reassessment and optimization of treatment based on urine culture and susceptibility results",[262,263,264],"Urinary Tract Infections","Antiobiotic Stewardship","Emerging Infectious Disease",[266,267,268,269,270],"Urinary tract infection","Urine culture and sensitivity tests","Antimicrobial stewarship","Side effect and adverse event of antibiotics","Fluoroquinolones and 3rd-generation cephalosporins",{"date":182,"type":31},{"date":273,"type":22},"2026-06-01",{"date":275,"type":22},"2027-01-01",{"name":37,"class":38},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":17,"minAge":284,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":51,"phases":288,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":72},"100556619","intervention-with-general-practitioners-to-improve-womens-participation-in-cervical-cancer-screening-100556619","NCT06527456","Intervention With General Practitioners to Improve Women's Participation in Cervical Cancer Screening","INDIGO","Inclusion Criteria:\n\n* Woman aged 25 to 65 living in Ile-De-France\n* Eligible for DOCCU (not hysterectomized, not followed for a pre-cancerous or cancerous lesion of the cervix)\n* Having declared the investigating general practitioner as a treating physician (MT) and whose MT practices in the territory of a CPTS in the UPEC area\n* Affiliate to a social security scheme or beneficiary of such a scheme\n\nExclusion Criteria:\n\n* Patient already included in a study on DOCCU\n* Patient excluded from organized screening (cervical cancer, hysterectomy).\n* Patient's opposition to participating in the study","25 Years","65 Years",{"count":287,"type":22},11200,[53],"In France, cervical cancer is the 12th most common female cancer with nearly 3,000 new cases per year.\n\nSince 2018, a national Organized Cervical Cancer Screening program (DOCCU) has been set up and concerns all asymptomatic women aged 25 to 65.\n\nThis program, managed by the Regional Cancer Screening Coordination Centers (CRCDC), invites women who have not taken a sample within the recommended time frame to consult for screening. However, only 59% of patients participated.\n\nThe intervention of the general practitioner, an essential player in prevention, could allow for better awareness.\n\nThe objective of the INDIGO study is to evaluate the effectiveness of the intervention of a general practitioner on the participation rate in the DOCCU of patients who are not up to date with their screening.",[291],"Cervical Cancer","2026-04-09",{"date":294,"type":31},"2026-04-14",{"date":296,"type":31},"2026-01-21",{"date":298,"type":22},"2027-08",{"name":37,"class":38},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":215,"minAge":80,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":51,"phases":310,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":324},"100604734","phase-2-using-a-fixed-dosage-of-follitropin-delta-for-ovarian-stimulation-for-intrauterine-insemination-rekovelle-for-intrauterine-successful-experience-rise-100604734","NCT07153367","Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)","RISE","Inclusion Criteria:\n\n* Normo-ovulatory patients\n* 18 - 38 included years old\n* BMI between 18 and 29 included kg\u002Fm²\n* Regular menstrual cycles\n* At least one healthy Fallopian tube\n* Normal uterus cavity\n* First treatment for IUI\n* Affiliation to the social security\n\nExclusion Criteria:\n\n* Endometriosis Stage III\n* Total mobile sperm count \\\u003C1 million\n* Severe spermatogenesis disorders\n* Women with Poly Cystic Ovary Syndrom\n* History of OHSS or excessive response to gonadotrophins\n* Chronic disease with contraindication to ovarian stimulation with gonadotrophins\n* Known genetic disease\n* Hypothalamus or pituitary tumors\n* Ovarian hypertrophy or ovarian cyst not due to polycystic ovary syndrome\n* Gynecological bleeding of unknown etiology\n* Ovarian, uterine or breast carcinoma\n* Primary ovarian failure\n* Genital malformations incompatible with pregnancy\n* Uterine fibroids incompatible with pregnancy\n* Protected persons (pregnant women, nursing mothers, person under guardianship, minors, persons deprived of liberty, and persons unable to give consent)\n* Tumors (including meningioma) whose development is known or suspected to be progesterone-dependent\n* History of hepatic dysfunction\n* Have been receiving progestogen therapy for more than 6 months\n* Known contraindication to hormonal treatments (progestogens or oestrogens), or with a history of adverse events related to their use\n* Previous thromboembolism events during or following the use of gonadotrophins or with high risk factors for thromboembolic events (venous or arterial)\n* Previous or current treatment with gonadotrophins\n* Hypersensitivity to the active substance or to any of the excipients\n* High risk of OHSS such as women with AMH ≥ 35 pmol\u002FL\n* History of severe uterine malformation (unicornuate or bicornuate uterus),\n* Past history of ovarian torsion\n* Uncontrolled thyroid dysfunction\n* Uncontrolled adrenal dysfunction\n* Hydrosalpynx\n* Breast pathologies not compatible with gonadotrophin stimulation\n* Use of infertility medications that could affect follicle stimulation and maturation such as GH\n* Participation in other interventional research\n* Not able to understand and sign the written informed consent form","38 Years",{"count":309,"type":22},80,[311],"PHASE2","The aim of this study is to evaluate the use of a fixed dose of 3.66 mcg of follitropin delta (Rekovelle) on ovarian response during ovarian stimulation for intrauterine insemination (IUI). The assumption is that this fixed dose will be effective while minimizing the risk of multiple pregnancies. A recent study demonstrated the efficacy of follitropin delta for ovarian stimulation in IUI, and it has been approved in France for controlled ovarian stimulation in assisted reproductive techniques such as in vitro fertilization (IVF) and IVF with intracytoplasmic sperm injection (ICSI). With an adapted dose of Rekovelle for patients with regular menstrual cycles, ovarian stimulation is optimized from the first attempt, promoting the development of two follicles to improve pregnancy chances while reducing the risk of multiple pregnancies. This approach aims to achieve pregnancy faster and provide a more comfortable treatment experience.",[314,315],"Infertility","Insemination","2026-04-03",{"date":318,"type":31},"2026-04-08",{"date":320,"type":31},"2025-12-17",{"date":322,"type":22},"2028-03-17",{"name":37,"class":38},5,{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":48,"enrollmentInfo":332,"targetDuration":4,"studyType":51,"phases":334,"briefSummary":335,"conditions":336,"keywords":342,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":355,"leadSponsor":357,"locationsCount":358},"100630908","phase-2-dexmedetomidine-for-invasive-ventilation-in-the-neonate-100630908","NCT07493785","Dexmedetomidine for Invasive Ventilation In the NEOnate","Double Blind, Multicenter, Randomized, Controlled Trial of Dexmedetomidine vs Placebo in Premature Neonates Receiving Invasive Ventilation","Above mentioned age limits (0 -10 weeks) apply to postnatal age. Inclusion criteria apply to gestational age at birth and postmenstrual age (in weeks).\n\nInclusion Criteria:\n\n* Neonates with a gestational age at birth \\\u003C 32 weeks of gestation and corrected gestational age \\\u003C 32 weeks postmenstrual age\n* Invasively ventilated with an expected or effective duration of ventilation \\> 24 hours at inclusion\n* Under mechanical ventilation since less than 72 hours at inclusion\n* With parental consent\n* Affiliated to or benefiting from a social security system\n\nExclusion Criteria:\n\n* Previous inclusion in this trial\n* Participation in another trial including analgesics or sedatives\n* Ongoing palliative care\n* Administration of dexmedetomidine or another alpha-2 agonist in the 96 previous hours\n* Hemodynamic compromise defined as any of: poor perfusion (increased capillary refill time, oliguria); hypotension defined as a mean blood pressure in mm Hg \\\u003C postmenstrual age in weeks; ongoing inotropic treatment with dopamine or dobutamine ≥ 5 µg\u002Fkg\u002Fmin, or any other inotropic drug at any dose, or need for more than one volume expansion (20 ml\u002Fkg) in the 6 previous hours\n* Pulmonary hypertension requiring pharmacological treatment\n* Heart rate \\\u003C100 bpm\n* Hepatic impairment defined as alanine aminotransferase level \\> 2 x normal upper limit\n* Known contra-indications to dexmedetomidine: hypersensitivity, atrioventricular block, acute cerebrovascular event\n* Hypersensitivity to the active substance or to any of the excipients contained in the medicine",{"count":333,"type":22},246,[311,218],"Despite the increasing use of non-invasive ventilation, a large majority of premature neonates still receive invasive ventilation during their NICU (neonatal intensive care unit) stay. Invasive ventilation is a unanimous source of discomfort and pain.\n\nAs opposed to the adult and pediatric population, routine use of opioids or midazolam is not recommended in ventilated neonates.\n\nAlthough opioids are the most frequently prescribed analgosedative drugs in ventilated premature neonates, their use is controversial because of the risk of respiratory depression - which can prolong invasive ventilation- and concerns on long-term neurodevelopment.\n\nDexmedetomidine, a selective alpha-2- adrenergic agonist routinely used in the adult ICU (intensive care unit), provides light sedation and some analgesia with no or little respiratory-depression effect. It also has neuroprotective properties after pediatric cardiac surgery and in neonatal animal models. Dexmedetomidine is thus a promising candidate drug in ventilated premature neonates that might reduce the duration of mechanical ventilation and preserve neurodevelopment in this vulnerable population.\n\nThe investigators hypothesize that the use of dexmedetomidine in ventilated premature neonates could decrease the need for opioids, facilitate extubation and thereby preserve long-term neurodevelopmental outcome.",[337,338,339,340,341],"Invasive Ventilation","Infant Pain","Infant Discomfort","Infant Neurodevelopment","Neonatal Respiratory Failure",[343,344,345,346,347,348,349,350],"Neonatology","Invasive mechanical ventilation","Analgesia","Dexmedetomidine","Neurodevelopment","Opioids","Pain","Withdrawal syndrome","2026-03-20",{"date":353,"type":31},"2026-03-25",{"date":273,"type":22},{"date":356,"type":22},"2034-08-01",{"name":37,"class":38},12,{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":215,"minAge":80,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":51,"phases":367,"briefSummary":368,"conditions":369,"keywords":373,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":72},"100629297","study-on-the-outcomes-of-patients-treated-in-gynecological-emergency-departments-for-pelvic-endometriosis-or-suspected-pelvic-endometriosis-100629297","NCT07472842","Study on the Outcomes of Patients Treated in Gynecological Emergency Departments for Pelvic Endometriosis or Suspected Pelvic Endometriosis","Inclusion Criteria :\n\n* Adult patient (aged 18 or over)\n* Patient consulting the gynecological emergency department at Créteil Hospital for\n* Known endometriosis or\n* Symptoms suggestive of endometriosis: dysmenorrhea, pelvic pain, cyclic dysuria, dyspareunia, cyclic dyschezia, infertility, rectal bleeding, chest pain, catamenial hematuria\n* Patient who speaks French and is able to understand the information sheet\n\nExclusion Criteria:\n\n* Minor or menopausal patient\n* Pregnant and breastfeeding patient\n* Other reason for consultation\n* Patient refusal\n* Patient not affiliated with a social security system\n* Patient cannot be contacted for the 3-months questionnaire",{"count":366,"type":22},200,[53],"Adult patients consulting the gynecological emergency department of CHI Créteil during the inclusion period for endometriosis or symptoms suggestive of endometriosis",[370,371,372],"Endometriosis","Pelvic Pain Syndrome","Chronic Gynaecological Disease",[374,375,376],"infertility","dysmenorrhea","pelvic pain","2026-03-12",{"date":379,"type":31},"2026-03-16",{"date":381,"type":31},"2025-10-16",{"date":383,"type":22},"2026-07-15",{"name":37,"class":38},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":17,"minAge":393,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":397,"conditions":398,"keywords":404,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":416},"100578261","prospective-multicentre-mixed-methods-study-to-explore-extubation-practices-and-respiratory-outcomes-in-extremely-preterm-neonates-100578261","NCT06808997","Prospective Multicentre Mixed Methods Study to Explore Extubation Practices and Respiratory Outcomes in Extremely Preterm Neonates.","Criteria and Reasons for Extubation and Non-extubation in Preterm Infants: A Mixed Methods Study Prospectively Exploring Extubation and Reintubation Practices in Extremely Preterm Infants, and Associated Respiratory Outcomes.","CERAINE","Inclusion Criteria:\n\n* Gestational age \\\u003C 28 weeks of gestation\n* Age at admission to the participating unit \\\u003C24 hours\n\nExclusion Criteria:\n\n* Parental opposition to their infant's clinical data collection\n* Participation in a research protocol with potential impact on extubation and\u002For duration of mechanical ventilation","1 Minute","5 Months",{"count":396,"type":22},100,"The purpose of this observational study is to learn about neonatologists' perceptions of extubation readiness and extubation and reintubation practices in extremely preterm infants in the first 2 weeks of life using prospective qualitative and quantitative data. Actual extubation readiness is defined as successful extubation, defined as no reintubation in the 7 days following extubation.\n\nKey research questions are: How do clinicians assess extubation readiness in this population? Does this assessment correlate with actual extubation success? What factors (reasons, clinical status, ventilatory parameters) are associated with extubation readiness? Patients born before 28 weeks gestational age and admitted to the neonatal intensive care unit (NICU) within the first 24 hours are be included. The attending physician will complete a prospectively administered questionnaire with open-ended and multiple-choice questions to daily assess the decision and rationale for extubation or non-extubation of patients mechanically ventilated during the first 15 days of life.\n\nPatient characteristics, respiratory outcomes, and mortality will be recorded until the end of hospitalisation and\u002For definitive weaning from any ventilatory support or supplemental oxygen.",[399,400,401,402,156,403],"PreTerm Neonate","Extubation Readiness","Extubation Failure","Respiratory Morbidity","Mechanical Ventilation",[405,406,407,408],"extremely preterm infants","extubation","mechanical ventilation","bronchopulmonary dysplasia","2026-03-11",{"date":377,"type":31},{"date":412,"type":31},"2025-02-17",{"date":414,"type":22},"2026-04-30",{"name":37,"class":38},31,{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":72},"100494193","evaluation-of-the-therapeutic-approach-of-aromatherapy-by-olfaction-of-essential-oils-in-association-with-hypnosis-in-the-management-of-patients-followed-for-cancer-100494193","NCT05714995","Evaluation of the Therapeutic Approach of Aromatherapy by Olfaction of Essential Oils in Association With Hypnosis in the Management of Patients Followed for Cancer","Evaluation of the Therapeutic Approach of Aromatherapy by Olfaction of Essential Oils in Association With Hypnosis in the Care of Patients Followed in Oncology for Cancer Within a Mobile Palliative Care Support Team (EMASP)","HYPNO-AROMA","Inclusion Criteria:\n\n* Patients aged ≥18 years\n* Patients followed in medical oncology and by the mobile palliative care support team\n* From the first line of chemotherapy\n* Patient requiring one of the following procedures:\n* Blood samples via a central catheter with a percutaneous implantable chamber, with a Huber needle\n* Peripheral venous samples\n* Change of dressing for cancerous lesion\n* Complete toilet in bed\n* Patients who have given their consent\n* Patient affiliated with a social security scheme\n\nExclusion Criteria:\n\n* Protected person under guardianship or curatorship,\n* Person deprived of liberty\n* Person unable to express consent\n* Pregnant woman and breastfeeding woman\n* History of allergy or intolerance to essential oils\n* Patients with cognitive or language disorders that make it impossible to answer the questionnaires\n* Psychotic disorders",{"count":426,"type":22},66,"Patients having the following gestures (blood test, change of dressing for cancerous lesion and complete toilet in bed) will be identified by the team of the medical oncology department.\n\nDuring the first contact (V0), the study will be presented to the patients in order to obtain their consent. Anxiety and well-being will be assessed before performing the gesture causing discomfort (gesture No.1). The gesture will then be performed and the patient's comfort will be evaluated after the gesture is performed in order to obtain the starting data for the study.\n\nPatients will be reviewed in consultation according to the time recommended for each type of gesture.\n\nDuring the second contact V1 (between 1 and 9 days after D0) anxiety and well-being will be assessed before performing the gesture causing discomfort (gesture No.2). Patients will then be randomized. After randomization, the first hypnosis session will be performed at the same time as gesture No. 2 and the patient's comfort will be evaluated after the gesture is performed. The patient will receive the self-hypnosis training on the same day.\n\nA period of 7 ± 2 days will be considered for the learning time of self-hypnosis.\n\nThe third contact will take place on day D7+\u002F-2 after V1. During this visit, anxiety and well-being will be assessed before performing the gesture causing discomfort (gesture No.3). Gesture No.3 will be carried out under the effect of self-hypnosis ± aromatherapy and the measurement of comfort will be carried out immediately afterwards",[429],"Cancer","2026-03-09",{"date":409,"type":31},{"date":433,"type":31},"2024-04-10",{"date":435,"type":22},"2026-10-10",{"name":37,"class":38},{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":446,"conditions":447,"keywords":449,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":460,"locationsCount":4},"100625671","experiences-of-early-postnatal-discharge-home-as-perceived-by-mothers-and-healthcare-professionals-100625671","NCT07425665","Experiences of Early Postnatal Discharge Home as Perceived by Mothers and Healthcare Professionals","Expériences du Retour à Domicile Post-natal précoce Par Les mères et Les Professionnels de santé : enquête Qualitative Sur Les Pratiques et Besoins","BbDom94","Selection of Maternity\n\nInclusion Criteria:\n\n* Public maternity unit in Val-de-Marne offering mothers early discharge home and willing to participate\n\nExclusion Criteria:\n\n* Maternity unit opposed to participation\n\nSelection of Home Care Professionals\n\nInclusion Criteria:\n\n-Healthcare professional involved in the follow-up of early postnatal discharge home for women in Val-de-Marne and willing to participate in the study\n\nInclusion Criteria:\n\n-Person with expertise in early return home and willing to participate",{"count":110,"type":22},"In recent years, the average length of stay in maternity units has decreased, leading to the development of early postnatal discharge home (EPDH) programs. Postnatal follow-up is a major public health issue, as it supports the physical and psychological well-being of mothers and newborns, helps parents adjust to their new roles, and promotes health prevention and education.\n\nInternational studies show that mothers expect longer and more comprehensive follow-up, particularly regarding child development, sexuality, contraception, and returning to work. In France, EPDH has existed since the early 2000s and is offered to low-risk mothers and newborns shortly after birth, with two or three follow-up visits at home or in healthcare facilities.\n\nAs these programs are expected to expand, there is a need to better understand the experiences and needs of both mothers and healthcare professionals. This qualitative study, conducted in the Val-de-Marne department, aims to explore how they experience early discharge at individual, organizational, and medical levels. It seeks to identify the factors that contribute to positive or negative postnatal experiences and to compare local findings with existing international research.",[448],"Health Services Research",[450,451,452,453],"Perinatal care","Mothers' experiences","Healthcare professionals' experiences","Healthcare organization","2026-02-16",{"date":456,"type":31},"2026-02-23",{"date":458,"type":22},"2026-03",{"date":298,"type":22},{"name":37,"class":38},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":215,"minAge":80,"maxAge":4,"enrollmentInfo":468,"targetDuration":469,"studyType":23,"phases":4,"briefSummary":470,"conditions":471,"keywords":475,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":488},"100543512","national-registry-of-surgical-treatment-and-percutaneous-cryoablation-of-parietal-endometriosis-100543512","NCT06356831","National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis","Endomercyo","Inclusion Criteria:\n\n* Presence of parietal endometriosis: with suggestive clinical and imaging criteria (MRI and ultrasound)\n* Symptomatic parietal endometriosis (VAS \\> 3 OR bothersome bleeding OR reported impact on quality of life)\n\nExclusion Criteria:\n\n* Endometriosis not affecting the anterior wall of the abdomen (as deep pelvic muscle: ilio-psoas, obturators, perineal, ischio-anal fossa)\n* Minor patient (\\\u003C 18 years)\n* Pregnant patient at any trimester\n* Patient with hemostasis disorders (constitutional or acquired)\n* Patient with systemic infection or localized scar infection upon inclusion.\n* Patient with contraindications to MRI\n* Female patient with a planned medical or surgical procedure for the duration of the study that may interfere with the proper conduct of the study.\n* Patient unable to understand the information provided\n* Patient who is not affiliated to the social security system\n* Patient under curatorship or tutorship\n* Patient with a nodule of primary or secondary malignant tumor origin",{"count":176,"type":22},"3 Years","National multicentric registry of a cohort of patient with suffering parietal endometriosis, carried out by a multidisciplinary radiosurgery team",[370,472,473,474],"Cryotherapy Effect","Surgical","Radiology",[476,477,478,479],"endometriosis","Cryo ablation","Surgical operation","radiology","2025-11-26",{"date":482,"type":31},"2025-11-28",{"date":484,"type":31},"2024-06-15",{"date":486,"type":22},"2028-01-31",{"name":37,"class":38},18,{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":17,"minAge":495,"maxAge":496,"enrollmentInfo":497,"targetDuration":4,"studyType":51,"phases":499,"briefSummary":500,"conditions":501,"keywords":504,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":324},"100467831","pharmacokinetics-pharmacodynamics-of-morphine-with-or-without-midazolam-administered-by-continuous-infusion-in-neonatal-intensive-care-100467831","NCT05371886","Pharmacokinetics-pharmacodynamics of Morphine With or Without Midazolam Administered by Continuous Infusion in Neonatal Intensive Care","Inclusion Criteria:\n\n* Neonates \\\u003C 45 weeks of corrected gestational age\n* Hospitalized in a Neonatal Intensive Care Unit\n* Undergoing mechanical ventilation\n* Patients that receive morphine alone or morphine and midazolam as continuous infusion\n* Affiliated to a social security system\n\nExclusion Criteria:\n\n* Current weight \\\u003C 600g\n* Neonates under palliative care\n* Therapeutic hypothermia for perinatal anoxia\n* Neonates who underwent a surgical procedure during the past 72 hours\n* Neonates receiving concomitantly a paralytic or another drug for sedation or analgesia other than morphine or midazolam (except for paracetamol\u002Facetaminophen)\n* Parents refusing that their child participate","20 Weeks","45 Weeks",{"count":498,"type":22},180,[53],"This study aims to describe a dose-effect relationship of morphine alone and morphine and midazolam administered as continuous infusion in neonates hospitalized in Neonatal intensive care unit and undergoing mechanical ventilation, through PKPD modelling.",[502,503],"Sedation Complication","Mechanical Ventilation in Neonates",[505,506,507,508,509],"morphine, midazolam","pharmacokinetics","pharmacodynamics","analgesia","neonates","2025-11-14",{"date":512,"type":31},"2025-11-17",{"date":514,"type":31},"2023-04-01",{"date":516,"type":22},"2027-05-01",{"name":37,"class":38},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":130,"enrollmentInfo":526,"targetDuration":4,"studyType":51,"phases":528,"briefSummary":529,"conditions":530,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":541},"100451375","phase-3-evaluation-of-the-efficacy-of-azithromycin-in-idiopathic-purulent-oedematous-sinusitis-in-adults-100451375","NCT05157685","Evaluation of the Efficacy of Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults","Evaluation of the Efficacy of 3-month Continuous Extended Treatment With Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults: a Multicentre Randomised Controlled Trial","SOPAZITHRO","Inclusion Criteria:\n\n* Patient older than 18 years and less than 70 years of age\n* Chronic rhinosinusitis (\\> 12 weeks of evolution) meeting the definition published in the European Paper Position2012 (1) and corresponding exclusively to the following endoscopic and CT criteria:\n\n  * Nasal endoscopy showing bilateral and diffuse involvement associating edema of the mucosa of the nasal cavities and meatus with the presence of mucopurulent secretions in these areas\n  * Nasosinus CT scan showing diffuse and bilateral pansinus opacities involving at least the maxillary sinuses and the anterior and posterior ethmoids\n* Persistent intractable purulent rhinosinusitis despite at least 2 antibiotic therapies\n* Signed informed consent of the patient\n* Membership in a health insurance plan or beneficiary\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* PCOS of identified primary cause (identified immune deficiency, cystic fibrosis, HIV)\n* Chronic non-purulent rhinosinusitis (nasosinusal polyposis, allergic rhinosinusitis)\n* Localized chronic suppurative rhinosinusitis (single sinus, unilateral, frontal or maxillary or sphenoidal)\n* Severe hepatic insufficiency (factor V level \\\u003C 50%)\n* Severe renal insufficiency (stage 4 (GFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2) and\u002For creatinine \\\u003C 40 ml\u002Fmin)\n* Severe heart failure (old age, ischemic heart disease, episode of recurrent cardiac arrest; hypotension, NYHA functional stage III-IV; widened QRS, complex ventricular arrhythmias; hyponatremia (Na \\\u003C135mmol\u002Fl); stage 4 renal failure (GFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2); severely depressed LVEF (\\\u003C 30%)\n* Documented moderate pre-existing sensorineural hearing loss with a mean pure tone threshold in the poorer ear in bone conduction \\>30 dB across all 3 frequencies (500, 1000 and 2000 Hz) or in only one ear (unilateral deafness).\n* Major cognitive impairment or lack of French language skills preventing completion of SNOT-22 and SF-36 questionnaires\n* Patient with galactose intolerance, total lactase deficiency or glucose-galactose malabsorption syndrome (rare hereditary diseases)\n* Patient with peanut or soy allergy\n* Patient allergic to macrolides\n* Patients who are intolerant or allergic to any of the excipients of azithromycin or placebo\n* Treatment with azithromycin in the previous 3 months\n* Long QT on ECG ((\\>440ms for male and \\>450ms for female) or cardiac arrhythmia or bradycardia (\\\u003C60btm).The calculation of the corrected QT should be carried out using the Bazett formula.\n* Hypokalemia or hypomagnesemia on blood ionogram\n* Confirmed or suspected atypical mycobacteriosis\n* Contraindicated drug combinations with macrolides (K-vitamins or drugs containing cisapride, colchicine, ergotamine or dihydroergotamine)\n* Cautionary drug combinations (non-inclusion criteria)\n\n  * Atorvastatin (Increased risk of concentration-dependent rhabdomyolysis-type adverse events due to decreased hepatic metabolism of the cholesterol-lowering drug.\n  * Ciclosporin (risk of increased ciclosporin blood levels and creatinine levels)\n  * Digoxin (increase in digoxemia due to increased absorption of digoxin), Drugs likely to cause torsades de pointes, in particular class IA (e.g. quinidine) and class III (e.g. amiodarone, sotalol) antiarrhythmics, antipsychotics (e.g. phenothiazines, pimozide), tricyclic antidepressants (e.g. citalopram), certain fluoroquinolones (e.g. moxifloxacin, levofloxacin) (increased risk of ventricular rhythm disturbances)\n  * Simvastatin (increased risk of rhabdomyolysis-type adverse effects (concentration-dependent), due to decreased hepatic metabolism of the cholesterol-lowering agent)\n  * Ivabradine (increased risk of ventricular rhythm disorders),\n  * Hypokalemic drugs\n  * Bradycardia drugs\n* Patients with severe cholestasis\n* Patients under guardianship or curatorship\n* Patients with hematologic malignancies who have undergone hematopoietic stem cell transplantation\n* History of facial radiotherapy\n* History of rhinosinus cancer\n* Participation in other category 1 research at the time of inclusion or in the month prior to inclusion",{"count":527,"type":22},230,[218],"Purulent Oedematous Sinusitis (POS) is a particular form of chronic rhinosinusitis observed in 2% of the general population. In spite of its heavy impact on the quality of life, There is no established recommendation for the treatment of primary POS. Long-term low-dose macrolides are currently proposed for these forms of chronic rhinosinusitis when conventional treatments (local corticosteroids, saline rinsing, iterative short courses of antibiotics targeted on pathogens, and surgical opening and drainage) have failed. This treatment with macrolides is currently applied off-label.\n\nThis study aims to assess the efficacy of macrolides in POS. An extensive workup is fulfilled to exclude other forms of chronic rhinosinusitis (Th2 biased inflammatory diseases, allergic diseases) (allergy, nasosinusal polyposis) or those due to cystic fibrosis or immune deficiency.",[531,532],"Sinusitis, Chronic","Sinus Infection Chronic","2025-08-28",{"date":535,"type":31},"2025-08-29",{"date":537,"type":31},"2022-11-21",{"date":539,"type":22},"2027-11-21",{"name":37,"class":38},13,{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":51,"phases":551,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":563},"100456742","mapping-and-characterization-of-alveolar-cells-during-smoking-and-chronic-obstructive-disease-100456742","NCT05227547","Mapping and Characterization of Alveolar Cells During Smoking and Chronic Obstructive Disease","CoStemCells","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Patient undergoing lung resection surgery (lobectomy, pneumonectomy, segmentectomy) for cancer or suspected cancer\n3. Acceptance to participate in the protocol\n4. Affiliated to a social security plan\n\nExclusion Criteria:\n\n1. Chronic autoimmune disease\n2. Patient under guardianship or curators\n3. Neo-adjuvant chemotherapy\n4. History of thoracic radiotherapy\n5. Pregnant woman\n6. Minor patient\n7. Person not able to consent\n8. Person deprived of liberty",{"count":550,"type":22},186,[53],"To evaluate the regenerative capacities of mesenchymal cells composing the microenvironment of alveolar type 2 cells in a population of patients, undergoing thoracic surgery for suspected cancer, who are smokers with and without COPD compared to non-smokers patients",[554,135],"Chronic Obstructive Lung Disease","2025-08-26",{"date":557,"type":31},"2025-09-02",{"date":559,"type":31},"2022-10-05",{"date":561,"type":22},"2030-10-05",{"name":37,"class":38},4,{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":570,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":17,"minAge":572,"maxAge":469,"enrollmentInfo":573,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":50},"100349136","research-of-the-consequences-on-the-digestive-tract-following-the-proposed-treatments-for-a-urinary-infection-in-children-100349136","NCT03825874","Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children","Comparison of the Impact on Digestive Portage of Broad Spectrum Beta-Lactamase-Producing Enterobacteriaceae (E-ESBLs) of Proposed Treatments in Outbreaks of Childhood Urinary Tract Infection","MIKA","Inclusion Criteria:\n\n* Infant and child (age ≥ 3 months and \\\u003C3 years)\n* Patient treated for febrile urinary tract infection as monotherapy with amikacin IV, ceftriaxone (IV or IM) or cefixime PO \\*\n* Whose parents read and understood the newsletter and whose express consent was collected\n* Patient affiliated to a social security scheme (Social Security or Universal Medical Coverage)\n\nExclusion Criteria:\n\n* Child treated with more than one antibiotic (eg treatment with dual therapy ceftriaxone \u002F cefotaxime and aminoglycoside)\n* Antibiotherapy in progress or discontinued in the previous 7 days\n* Hospitalized child\n* Refusal of one of the parents","3 Months",{"count":366,"type":22},"The emergence of extended-spectrum beta-lactamase-producing Enterobacteriaceae (E-ESBL) is a major public health problem. It leads more frequent prescription of penems with the risk of emergence and spread of strains producing carbapenemases, which may be resistant to all known antibiotics. A policy of savings of penems is desirable. Among the alternatives to penems, amikacin is in the foreground. It remains active on the majority of E-ESBL strains. Some risk factors for E-ESBL emergence are known: recent antibiotic therapy (particularly quinolones and cephalosporins third generation), previous hospitalization or residence in a high endemic country.\n\nIn pediatrics, E-ESBLs are primarily responsible for urinary tract infection. In France, E-ESBLs represent about 10% of the strains responsible for urinary tract infections. The Pathology Group Pediatric Infectious (GPIP) of the French Society of Pediatrics (SFP) and the Society of Infectious Pathology French Language (SPILF) have proposed different therapeutic options to treat febrile UTIs in children: amikacin intravenous; intravenous (IV) ceftriaxone or intramuscular (IM); or cefixime per-os (PO).\n\nThe objective of this study is to compare the emergence of E-ESBLs in stools of children after febrile UTIs treatment with amikacin IV versus ceftriaxone or cefixime.",[262,576],"Urinary Tract Infections in Children",{"date":578,"type":31},"2025-08-27",{"date":580,"type":31},"2019-01-19",{"date":582,"type":22},"2026-07",{"name":37,"class":38},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":215,"minAge":80,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":593,"conditions":594,"keywords":598,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":72},"100604218","comparison-of-operative-hysteroscopy-performed-in-the-operating-room-versus-outpatient-settings-100604218","NCT07146659","Comparison of Operative Hysteroscopy Performed in the Operating Room Versus Outpatient Settings","Comparison of Operative Hysteroscopy Performed in the Operating Room Versus Outpatient Settings : A Prospective Observational Study","Inclusion Criteria:\n\n* Women aged ≥ 18 years\n\n  -⁃ Undergoing operative hysteroscopy for intrauterine pathology\n* Able to provid e informed non-opposition\n* French-speaking\n\nExclusion Criteria:\n\n* Patients with contraindications to hysteroscopy\n* Pregnancy\n* Inability to complete follow-up",{"count":592,"type":22},400,"This is an observational prospective monocentric study which aims to compare operative hysteroscopies performed in the operating room under general or loco-regional anesthesia and those performed outside the operating room (outpatient operative hysteroscopy). The primary outcome is the success rate of the procedure. Secondary outcomes include postoperative pain, patient satisfaction, complications, and time to return to work.",[595,596,597],"Fibroid Uterus","Polyp Uterus","Retained Products of Conception",[599,600,601,602,603,604],"Hysteroscopy","Operative hysteroscopy","Outpatient ambulatory","Patient satisfaction","Outpatient hysteroscopy","Complications","2025-08-21",{"date":533,"type":31},{"date":608,"type":31},"2025-07-01",{"date":610,"type":22},"2027-05-31",{"name":37,"class":38},{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":51,"phases":622,"briefSummary":623,"conditions":624,"keywords":626,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":488},"100544432","phase-2-comparison-of-two-antibiotic-regimens-for-the-treatment-of-early-airways-infection-with-pa-in-adults-with-bronchiectasis-100544432","NCT06368804","Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis","Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With Pseudomonas Aeruginosa in Adults With Bronchiectasis: a Non-inferiority Randomized Controlled Trial.","ANTEIPA","Inclusion Criteria:\n\n* ≥18 years of age\n* Diagnosis of bronchiectasis on thoracic CT-scan\n* Recent isolation of P. aeruginosa (PA) in a respiratory sample (spontaneous or induced sputum or other lower respiratory tract sample obtained by bronchoscopy) within the last 3 months, with a PA positive respiratory sample obtained ≤ 3 weeks before randomization\n* Patient either Pseudomonas naive (i.e., never previously isolated PA) or Pseudomonas free (i.e., infection-free for ≥1 year, proven by at least two PA negative respiratory sample during the last year)\n* Patient affiliated with the French health care system\n* Able to understand and sign a written informed consent form\n\nExclusion Criteria:\n\n* Confirmed diagnosis of cystic fibrosis\n* Pregnancy or breastfeeding\n* Women of childbearing potential (after the first menstrual period and until menopause or permanent sterility (hysterectomy, bilateral salpingectomy and bilateral oophorectomy)) who refuse to use effective contraception (hormonal or mechanical) for 3 months and\u002For to undergo pregnancy tests at baseline, 1 month and 3 months after baseline.\n* Isolation of PA in a respiratory specimen (spontaneous or induced sputum or other lower respiratory tract specimen obtained by bronchoscopy) more than 3 months to 12 months prior to randomization.\n* PA resistant to ciprofloxacin or ceftazidime\n* Severe exacerbation requiring admission to an intensive care unit (e.g. for non-invasive ventilatory support, invasive mechanical ventilation, catecholamine or any other organ supportive therapy)\n* Prior severe reaction, hypersensitivity reaction or other contraindication to any of the treatments in study (ciprofloxacin, beta-lactam, colistimethate sodium)\n* Prior severe bronchospasm attributed to a nebulization\n* Patients already receiving PA suppressive therapy with an inhaled antibiotic (long-term azithromycin therapy accepted)\n* Prior PA-eradication antibiotic treatment (systemic antibiotic(s) active against PA for ≥ 14 days or nebulized anti-PA antibiotic) within the last year\n* Antibiotic treatment active against PA (anti-PA beta-lactam antibiotic and\u002For FQ and\u002For aminoglycoside) for more than 3 days before randomisation\n* Active cancer or haematological malignancy under active therapy\n* Systemic corticosteroid therapy ≥ 20 mg\u002Fd. prednisone equivalent for a predictable duration \\> 4 weeks\n* Non-tuberculous mycobacterial infection or positive non-tuberculous mycobacterial respiratory specimen within 1 year prior to inclusion\n* Severe chronic renal failure defined by a creatinine clearance (Cockcroft or MDRD) ≤ 30 mL\u002Fmin\u002F1.73m2 or chronic haemodialysis\n* Severe hepatic impairment\n* Long-term oxygen therapy and\u002For noninvasive mechanical ventilation for chronic respiratory insufficiency (except continuous positive airway pressure for OSA) and\u002For forced expiratory volume at one second (FEV1) \\\u003C25% of predicted value.\n* Patient participating to another interventional clinical trial",{"count":621,"type":22},196,[311],"Chronic airways infection with Pseudomonas aeruginosa (PA) is associated with increased frequency of exacerbations, deterioration in quality of life and increased mortality in adult patients with bronchiectasis. Current guidelines suggest the prescription of an eradication antibiotic treatment for a first episode of PA infection (early PA infection). Several antibiotic regimens may be proposed, ranging from a monotherapy with oral fluoroquinolone (FQ) to an intravenous cotherapy with the addition of inhaled antibiotics that seems to improve the rate of PA eradication. As no study strictly favoured one regimen, current practices are heterogeneous and could certainly benefit from stronger evidence, with both medical and economic impact.",[625],"Bronchiectasis",[627],"Non cystic fibrosis bronchiectasis","2025-07-16",{"date":630,"type":31},"2025-07-17",{"date":632,"type":31},"2024-09-15",{"date":634,"type":22},"2028-09-15",{"name":37,"class":38},""]